BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bajaj JS. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Aliment Pharmacol Ther. 2016;43 Suppl 1:11-26. [PMID: 26618922 DOI: 10.1111/apt.13435] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 7.3] [Reference Citation Analysis]
2 Krag A, Schuchmann M, Sodatonou H, Pilot J, Whitehouse J, Strasser SI, Hudson M. Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients. Hepatol Med Policy 2018;3:4. [PMID: 30288327 DOI: 10.1186/s41124-017-0029-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Henkel S, Vetterly C, Squires R, McKiernan P, Squires J. Pharmacological management of portal hypertension and its complications in children: lessons from adults and opportunities for the future. Expert Opin Pharmacother 2021;22:291-304. [PMID: 33074032 DOI: 10.1080/14656566.2020.1825685] [Reference Citation Analysis]
4 Dong TS, Jacobs JP, Hussain SK. Microbial Profiles of Cirrhosis in the Human Small Intestine. Curr Gastroenterol Rep 2019;21:50. [PMID: 31444636 DOI: 10.1007/s11894-019-0717-2] [Reference Citation Analysis]
5 Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018;47:192-202. [PMID: 29083037 DOI: 10.1111/apt.14397] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 15.6] [Reference Citation Analysis]
6 Kimer N, Gudmann NS, Pedersen JS, Møller S, Nielsen MJ, Leeming DJ, Karsdal MA, Møller HJ, Bendtsen F, Grønbæk H. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. PLoS One 2018;13:e0203200. [PMID: 30183743 DOI: 10.1371/journal.pone.0203200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bajaj JS, Barbara G, DuPont HL, Mearin F, Gasbarrini A, Tack J. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Dig Liver Dis 2018;50:741-9. [PMID: 29807873 DOI: 10.1016/j.dld.2018.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
8 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
9 Montagnese S, Russo FP, Amodio P, Burra P, Gasbarrini A, Loguercio C, Marchesini G, Merli M, Ponziani FR, Riggio O, Scarpignato C. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51:190-205. [PMID: 30606696 DOI: 10.1016/j.dld.2018.11.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
10 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
11 Acharya C, Bajaj JS. Current Management of Hepatic Encephalopathy. Am J Gastroenterol. 2018;113:1600-1612. [PMID: 30002466 DOI: 10.1038/s41395-018-0179-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
12 Zhang J, Wieser A, Lin H, Fan Y, Li H, Schiergens TS, Mayerle J, Gerbes AL, Steib CJ. Pretreatment with zinc protects Kupffer cells following administration of microbial products. Biomed Pharmacother 2020;127:110208. [PMID: 32417689 DOI: 10.1016/j.biopha.2020.110208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
14 Li H, Xiang Y, Zhu Z, Wang W, Jiang Z, Zhao M, Cheng S, Pan F, Liu D, Ho RCM, Ho CSH. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. J Neuroinflammation 2021;18:254. [PMID: 34736493 DOI: 10.1186/s12974-021-02303-y] [Reference Citation Analysis]
15 Swaminathan M, Ellul MA, Cross TJ. Hepatic encephalopathy: current challenges and future prospects. Hepat Med. 2018;10:1-11. [PMID: 29606895 DOI: 10.2147/hmer.s118964] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
16 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
17 Coronel-castillo C, Contreras-carmona J, Frati-munari A, Uribe M, Méndez-sánchez N. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Revista de Gastroenterología de México (English Edition) 2020;85:56-68. [DOI: 10.1016/j.rgmxen.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Kawaguchi T, Suzuki F, Imamura M, Murashima N, Yanase M, Mine T, Fujisawa M, Sato I, Yoshiji H, Okita K, Suzuki K. Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials. Hepatol Res 2019;49:404-18. [PMID: 30589492 DOI: 10.1111/hepr.13300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
19 Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol 2021;12:718783. [PMID: 34393832 DOI: 10.3389/fphys.2021.718783] [Reference Citation Analysis]
20 Balbinot P, Leone S, Testino G, Caputo F. Hospital readmission of patients with hepatic encephalopathy: Is the introduction of the formal caregiver useful in care management? Dig Liver Dis 2020;52:358-9. [PMID: 31874833 DOI: 10.1016/j.dld.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
21 Mangas-Losada A, García-García R, Leone P, Ballester MP, Cabrera-Pastor A, Urios A, Gallego JJ, Martínez-Pretel JJ, Giménez-Garzó C, Revert F, Escudero-García D, Tosca J, Ríos MP, Montón C, Durbán L, Aparicio L, Montoliu C, Felipo V. Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. J Transl Med 2019;17:293. [PMID: 31462286 DOI: 10.1186/s12967-019-2046-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
22 Woodhouse C, Singanayagam A, Patel VC. Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. Clin Med (Lond) 2020;20:493-500. [PMID: 32934044 DOI: 10.7861/clinmed.2020-0676] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Manzhalii E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment. World J Hepatol 2022; 14(3): 634-646 [DOI: 10.4254/wjh.v14.i3.634] [Reference Citation Analysis]
24 Yuan Y, Wang X, Xu X, Liu Y, Li C, Yang M, Yang Y, Ma Z. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. ACS Infect Dis 2020;6:820-31. [DOI: 10.1021/acsinfecdis.9b00374] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 2017;65:592-603. [PMID: 27775818 DOI: 10.1002/hep.28898] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
26 Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, Fujinaga Y, Tsuji Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Fukui H, Yoshiji H. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. Int J Mol Sci 2021;22:6921. [PMID: 34203178 DOI: 10.3390/ijms22136921] [Reference Citation Analysis]
27 Madsen M, Kimer N, Bendtsen F, Petersen AM. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. Scand J Gastroenterol 2021;56:560-9. [PMID: 33840331 DOI: 10.1080/00365521.2021.1899277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Kimer N, Pedersen JS, Tavenier J, Christensen JE, Busk TM, Hobolth L, Krag A, Al-Soud WA, Mortensen MS, Sørensen SJ, Møller S, Bendtsen F; members of the CoRif study group. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. J Gastroenterol Hepatol 2018;33:307-14. [PMID: 28671712 DOI: 10.1111/jgh.13852] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
29 Lajczak NK, Saint-Criq V, O'Dwyer AM, Perino A, Adorini L, Schoonjans K, Keely SJ. Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic epithelial cells. FASEB J 2017;31:3848-57. [PMID: 28487283 DOI: 10.1096/fj.201601365R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Bajic D, Niemann A, Hillmer A, Mejias-luque R, Bluemel S, Docampo M, Funk MC, Tonin E, Boutros M, Schnabl B, Busch DH, Miki T, Schmid RM, van den Brink MRM, Gerhard M, Stein-thoeringer CK. Gut Microbiota-Derived Propionate Regulates the Expression of Reg3 Mucosal Lectins and Ameliorates Experimental Colitis in Mice. Journal of Crohn's and Colitis 2020;14:1462-72. [DOI: 10.1093/ecco-jcc/jjaa065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
31 Balzano T, Leone P, Ivaylova G, Castro MC, Reyes L, Ramón C, Malaguarnera M, Llansola M, Felipo V. Rifaximin Prevents T-Lymphocytes and Macrophages Infiltration in Cerebellum and Restores Motor Incoordination in Rats with Mild Liver Damage. Biomedicines 2021;9:1002. [PMID: 34440206 DOI: 10.3390/biomedicines9081002] [Reference Citation Analysis]
32 Rajpurohit S, Musunuri B, Shailesh, Mohan PB, Shetty S. Novel Drugs for the Management of Hepatic Encephalopathy: Still a Long Journey to Travel. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.01.012] [Reference Citation Analysis]
33 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
34 Lange CM, Moreau R. Immunodysfunction in Acute-on-Chronic Liver Failure. Visc Med 2018;34:276-82. [PMID: 30345285 DOI: 10.1159/000488690] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
35 Rocco A, Sgamato C, Compare D, Coccoli P, Nardone OM, Nardone G. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives. Front Cell Dev Biol 2021;9:748253. [PMID: 34900994 DOI: 10.3389/fcell.2021.748253] [Reference Citation Analysis]
36 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
37 Campanella B, Onor M, Lomonaco T, Benedetti E, Bramanti E. HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota. Anal Bioanal Chem 2019;411:7551-62. [PMID: 31641822 DOI: 10.1007/s00216-019-02158-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Liu J, Xu Y, Jiang B. Novel Insights Into Pathogenesis and Therapeutic Strategies of Hepatic Encephalopathy, From the Gut Microbiota Perspective. Front Cell Infect Microbiol 2021;11:586427. [PMID: 33692964 DOI: 10.3389/fcimb.2021.586427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Yim HJ, Suh SJ, Jung YK, Yim SY, Seo YS, Lee YR, Park SY, Jang JY, Kim YS, Kim HS, Kim BI, Um SH. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. American Journal of Gastroenterology 2018;113:1167-76. [DOI: 10.1038/s41395-018-0168-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
40 Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H. Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatol Res 2019;49:1406-13. [DOI: 10.1111/hepr.13415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
42 Nathwani R, Mullish B, Kockerling D, Cole A, Selvapatt N, Dhar A. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. EMJ. [DOI: 10.33590/emj/21-00026] [Reference Citation Analysis]
43 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Flatt E, McLin VA, Braissant O, Pierzchala K, Mastromarino P, Mitrea SO, Sessa D, Gruetter R, Cudalbu C. Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE. Sci Rep 2021;11:17988. [PMID: 34504135 DOI: 10.1038/s41598-021-97018-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Bartoletti M, Rinaldi M, Pasquini Z, Scudeller L, Piano S, Giacobbe DR, Maraolo AE, Bussini L, Del Puente F, Incicco S, Angeli P, Giannella M, Baldassarre M, Caraceni P, Campoli C, Morelli MC, Cricca M, Ambretti S, Gentile I, Bassetti M, Viale P. Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre case-control-control study. Clin Microbiol Infect 2021;27:276-82. [PMID: 32360775 DOI: 10.1016/j.cmi.2020.04.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol 2019;54:209-17. [PMID: 30392013 DOI: 10.1007/s00535-018-1521-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
47 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
48 Li M, Li K, Tang S, Lv Y, Wang Q, Wang Z, Luo B, Niu J, Zhu Y, Guo W, Bai W, Wang E, Xia D, Wang Z, Li X, Yuan J, Yin Z, Trebicka J, Han G. Restoration of the gut microbiota is associated with a decreased risk of hepatic encephalopathy after TIPS. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100448] [Reference Citation Analysis]
49 Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366 [PMID: 29307995 DOI: 10.3748/wjg.v23.i47.8355] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
50 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
51 Ballester M, Gallego J, Fiorillo A, Casanova-ferrer F, Giménez-garzó C, Escudero-garcía D, Tosca J, Ríos M, Montón C, Durbán L, Ballester J, Benlloch S, Urios A, San-miguel T, Kosenko E, Serra M, Felipo V, Montoliu C. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-06416-z] [Reference Citation Analysis]
52 Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World J Hepatol 2019; 11(6): 489-512 [PMID: 31293718 DOI: 10.4254/wjh.v11.i6.489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]